Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of clemizole hydrochloride EPX-100 as an additional treatment for children and adults with Dravet syndrome, a rare and severe form of epilepsy. This is a Phase 3, randomized, double-blind, placebo-controlled study conducted across multiple centers. The trial aims to assess whether clemizole HCl can help reduce the number of motor seizures experienced by participants whose seizures are not fully controlled by other anti-epileptic drugs AEDs. Participants will be randomly assigned to receive either clemizole HCl or a matching placebo twice daily during the double-blind phase, which includes a dose titration period followed by a maintenance period lasting up to 16 weeks. Those who complete this phase may have the option to join an open-label extension phase where they will receive clemizole HCl. The investigational treatments are given as oral solutions. Throughout the study, participants will be monitored for changes in the frequency of countable motor seizures over 28-day periods compared to their baseline seizure counts. Other assessments include seizure-free days, use of rescue AEDs, and clinician and caregiver evaluations of improvement. Safety will be closely followed by tracking adverse events. The overall participation may last up to 20 weeks or longer if the optional extension is chosen.